Profit

Biocon Launches New Hepatitis-C Drug

PUBLISHED ON: December 24, 2015 | Duration: 2 min, 22 sec

   
loading..
Kiran Mazumdar-Shaw, CMD of Biocon, said at the moment the Indian market for this new drug is approaching Rs 200 crore and it is expected to rise to Rs 500 crore.
ALSO WATCH
Kiran Mazumdar Shaw Talks About Key Takeaways from Budget 2018

................................ Advertisement ................................

................................ Advertisement ................................